duchenne muscular dystrophy sarepta

News

Duchenne muscular dystrophy, genetics

Following second patient death, Duchenne muscular dystrophy families deserve answers about Elevidys

Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t getting answers from Sarepta.

Associated Press News on MSN · 4d

Second patient death reported with gene therapy for muscular dystrophy

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

BioPharma Dive · 4d

Second Duchenne patient dies after receiving Sarepta gene therapy

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain patients while it evaluates new safety precautions.

STAT1d

What’s next for Sarepta Therapeutics with gene therapy under fire?

The death of a boy with Duchenne muscular dystrophy, tied to a gene therapy, is above all a tragedy. But it is also ...

Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered ...

Why Sarepta Therapeutics (SRPT) Stock Is Down Today

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a ...

Managed Healthcare Executive4d

Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...

MedCity News4d

Sarepta Stops Stop Shipments of Muscular Dystrophy Gene Therapy After Second Patient Death

A patient has died after receiving Sarepta Therapeutics’ approved gene therapy for Duchenne muscular dystrophy — the second fatality reported by the company in the past three months.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results